Hôpital Privé du Confluent, 2-4 Rue Eric Tabarly, 44200, Nantes, France.
Centre Hospitalier Universitaire Tours, Tours, France.
J Interv Card Electrophysiol. 2023 Aug;66(5):1201-1209. doi: 10.1007/s10840-022-01440-5. Epub 2022 Dec 2.
In patients with cardiac resynchronization therapy defibrillators (CRT-Ds), the need for implantable cardioverter-defibrillator (ICD) back-up may be questionable at time of CRT-D replacement (REP) if ICD implant criteria are no longer met due to an improved left ventricular ejection fraction (LVEF) and if no major ventricular arrhythmic event (VAE) occurred during the CRT-D lifetime. The aim of our study was to assess the relevance of ICD back-up and predictors of VAE after REP in primary prevention CRT-D patients.
The prospective, observational, international BioCONTINUE study investigated the rate of patients with at least 1 sustained VAE (sVAE) post-REP and searched for predictive factors of sVAE.
Two hundred seventy-six patients (70 ± 10 years, 77% men, mean LVEF 40.6 ± 12.6%) were followed for 28.4 ± 10.2 months. The rate of patients with sVAE was 8.3%, 10.3%, and 21.2% at 1, 2, and 4 years post-REP. Patients without persistent ICD indication at REP still had a sVAE rate of 5.7% (95% CI 2.3-11.5%) at 2 years. In multivariate analysis, predictive factors of subsequent sVAE were (i) persistent ICD indication (hazard ratio (HR) 3.6; 95% CI 1.6-8.3; p = 0.003); (ii) 64-72 years of age as compared to ≥ 79 years (HR 3.7; 95% CI 1.4-9.7; p = 0.008); and (iii) ischemic heart disease (HR 4.4; 95% CI 2.1-9.3; p < 0.0001).
The risk of sVAE (21.2% at 4 years post-REP) depends on age, ischemic heart disease, and ICD indication at the time of REP. A non-trivial risk of sVAE remains in patients without persistent ICD indication.
NCT02323503.
在心脏再同步治疗除颤器(CRT-D)患者中,如果由于左心室射血分数(LVEF)改善而不再符合植入式心脏转复除颤器(ICD)植入标准,并且在 CRT-D 寿命期间未发生重大室性心律失常事件(VAE),则在 CRT-D 更换(REP)时可能对 ICD 备用的需求产生疑问。我们的研究目的是评估在原发性预防 CRT-D 患者中,REP 后 ICD 备用的相关性和 VAE 的预测因素。
前瞻性、观察性的国际 BioCONTINUE 研究调查了至少发生 1 次持续性 VAE(sVAE)的患者比例,以及寻找 sVAE 的预测因素。
276 名患者(70±10 岁,77%为男性,平均 LVEF 为 40.6±12.6%)随访了 28.4±10.2 个月。REP 后 1、2 和 4 年时,sVAE 患者的比例分别为 8.3%、10.3%和 21.2%。在 REP 时仍无持续 ICD 适应证的患者,2 年时 sVAE 发生率仍为 5.7%(95%CI 2.3-11.5%)。多变量分析表明,随后发生 sVAE 的预测因素为:(i)持续存在 ICD 适应证(风险比(HR)为 3.6;95%CI 1.6-8.3;p=0.003);(ii)64-72 岁与≥79 岁相比(HR 为 3.7;95%CI 1.4-9.7;p=0.008);和(iii)缺血性心脏病(HR 为 4.4;95%CI 2.1-9.3;p<0.0001)。
sVAE(REP 后 4 年时为 21.2%)的风险取决于年龄、缺血性心脏病和 REP 时的 ICD 适应证。在没有持续 ICD 适应证的患者中,sVAE 的风险仍然存在。
NCT02323503。